Vipul Jairath
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial
Jairath, Vipul; Zou, Guangyong; Wang, Zhongya; Adsul, Shashi; Colombel, Jean-Frederic; D’Haens, Geert R; Freire, Marcelo; Moran, Gordon W; Peyrin-Biroulet, Laurent; Sandborn, William J; Sebastian, Shaji; Travis, Simon; Vermeire, Séverine; Radulescu, Gabriela; Sigler, Julie; Hanžel, Jurij; Ma, Christopher; Sedano, Rocio; McFarlane, Stefanie C; Arya, Naveen; Beaton, Melanie; Bossuyt, Peter; Danese, Silvio; Green, Daniel; Harlan III, William; Horynski, Marek; Klopocka, Maria; Petroniene, Rima; Silverberg, Mark S; Wolanski, Lukasz; Feagan, Brian G
Authors
Guangyong Zou
Zhongya Wang
Shashi Adsul
Jean-Frederic Colombel
Geert R D’Haens
Marcelo Freire
GORDON MORAN GORDON.MORAN@NOTTINGHAM.AC.UK
Professor of Gastroenterology
Laurent Peyrin-Biroulet
William J Sandborn
Shaji Sebastian
Simon Travis
Séverine Vermeire
Gabriela Radulescu
Julie Sigler
Jurij Hanžel
Christopher Ma
Rocio Sedano
Stefanie C McFarlane
Naveen Arya
Melanie Beaton
Peter Bossuyt
Silvio Danese
Daniel Green
William Harlan III
Marek Horynski
Maria Klopocka
Rima Petroniene
Mark S Silverberg
Lukasz Wolanski
Brian G Feagan
Abstract
Introduction: Symptoms, endoscopy and histology have been proposed as therapeutic targets in ulcerative colitis (UC). Observational studies suggest that the achievement of histologic remission may be associated with a lower risk of complications, compared with the achievement of endoscopic remission alone. The actiVE ulcerative colitis, a RanDomIsed Controlled Trial (VERDICT) aims to determine the optimal treatment target in patients with UC. Methods and analysis: In this multicentre, prospective randomised study, 660 patients with moderate to severe UC (Mayo rectal bleeding subscore [RBS] ≥1; Mayo endoscopic score [MES] ≥2) are randomly assigned to three treatment targets: corticosteroid-free symptomatic remission (Mayo RBS=0) (group 1); corticosteroid-free endoscopic remission (MES ≤1) and symptomatic remission (group 2); or corticosteroid-free histologic remission (Geboes score <2B.0), endoscopic remission and symptomatic remission (group 3). Treatment is escalated using vedolizumab according to a treatment algorithm that is dependent on the patient’s baseline UC therapy until the target is achieved at weeks 16, 32 or 48. The primary outcome, the time from target achievement to a UC-related complication, will be compared between groups 1 and 3 using a Cox proportional hazards model. Ethics and dissemination: The study was approved by ethics committees at the country level or at individual sites as per individual country requirements. A full list of ethics committees is available on request. Study results will be disseminated in peer-reviewed journals and at scientific meetings. Trial registration number: EudraCT: 2019-002485-12; NCT04259138.
Citation
Jairath, V., Zou, G., Wang, Z., Adsul, S., Colombel, J.-F., D’Haens, G. R., Freire, M., Moran, G. W., Peyrin-Biroulet, L., Sandborn, W. J., Sebastian, S., Travis, S., Vermeire, S., Radulescu, G., Sigler, J., Hanžel, J., Ma, C., Sedano, R., McFarlane, S. C., Arya, N., …Feagan, B. G. (2024). Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial. BMJ Open Gastroenterology, 11(1), Article e001218. https://doi.org/10.1136/bmjgast-2023-001218
Journal Article Type | Article |
---|---|
Acceptance Date | Dec 6, 2023 |
Online Publication Date | Feb 9, 2024 |
Publication Date | 2024 |
Deposit Date | Dec 13, 2023 |
Publicly Available Date | Feb 9, 2025 |
Journal | BMJ Open Gastroenterology |
Electronic ISSN | 2054-4774 |
Publisher | BMJ Publishing Group |
Peer Reviewed | Peer Reviewed |
Volume | 11 |
Issue | 1 |
Article Number | e001218 |
DOI | https://doi.org/10.1136/bmjgast-2023-001218 |
Keywords | ENDOSCOPY, ULCERATIVE COLITIS, HISTOPATHOLOGY |
Public URL | https://nottingham-repository.worktribe.com/output/28426716 |
Publisher URL | https://bmjopengastro.bmj.com/content/11/1/e001218 |
Files
This file is under embargo until Feb 9, 2025 due to copyright restrictions.
You might also like
Clinical predictors of thiopurine-related adverse events in Crohn's disease
(2015)
Journal Article
Colectomy is a risk factor for venous thromboembolism in ulcerative colitis
(2015)
Journal Article
Orbital inflammatory complications of Crohn’s disease: a rare case series
(2018)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search